Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition

Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OncoTargets and therapy 2019-01, Vol.12, p.495-508
Hauptverfasser: Wu, Junfeng, Li, Wei, Ning, Jinzhuo, Yu, Weimin, Rao, Ting, Cheng, Fan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 508
container_issue
container_start_page 495
container_title OncoTargets and therapy
container_volume 12
creator Wu, Junfeng
Li, Wei
Ning, Jinzhuo
Yu, Weimin
Rao, Ting
Cheng, Fan
description Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer. Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities. These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.
doi_str_mv 10.2147/OTT.S183940
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6331189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687140483</galeid><sourcerecordid>A687140483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rp65b0EBBGkYz7aJL0RhkFXYXBhnb0OaXPaZukkY5IK-3_8oWbccZ0RyUUOJ895k3PyFsVLgheUVOL91Waz-EYkayr8qDgnRMiSNww_PorPimcx3mLMuaTV0-KM5YgTKs-Ln2vvBuS867yxObr-ukQ3qyVBSYcBUkRbe13Wkpb1DmlnUOddCradE0SUPEojoF3wQ4AYrXe_ERPmAeWEjUm7DpDvUTtpYyCgbp_IG0xTLh-Dn4cRLTeXotyCsTqBQXpOfjfq4Q5ZN9rWpiz7vHjS6ynCi8N-Udx8-rhZfS7XV5dfVst12XFSp9JoLirS6pa3NTOYUNPUmveyxbyS0ErS4FYKTEnDW9EzIYTpQFMgDXAmTc8uig_3uru5zQ_qIPeqJ7ULdqvDnfLaqtMTZ0c1-B-KM0aIbLLA24NA8N9niEltbdx3qx34OSpKRMOauiYko6__QW_9HFxuT1FKMyNr3PylBj2Bsq73-d5uL6qWXApS4UqyTC3-Q-VlYGvzj0Fvc_6k4M1RwQh6SmP007wfdjwF392DXfAxBugfhkGw2rtPZfepg_sy_ep4fg_sH7uxX9FN1Js</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229558509</pqid></control><display><type>article</type><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><source>Taylor &amp; Francis Open Access</source><source>DOVE Medical Press Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</creator><creatorcontrib>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</creatorcontrib><description>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer. Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities. These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S183940</identifier><identifier>PMID: 30666128</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antisense RNA ; Apoptosis ; Autophagy ; Biomarkers ; Bladder cancer ; Cancer ; Cancer therapies ; Cell cycle ; Cell growth ; Colorectal cancer ; Development and progression ; Drug resistance ; Drug therapy ; Health aspects ; Health risk assessment ; Immunohistochemistry ; Liver cancer ; Oncology, Experimental ; Original Research ; Polymerase chain reaction ; Tumorigenesis</subject><ispartof>OncoTargets and therapy, 2019-01, Vol.12, p.495-508</ispartof><rights>COPYRIGHT 2019 Dove Medical Press Limited</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Wu et al. This work is published and licensed by Dove Medical Press Limited 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</citedby><orcidid>0000-0003-3691-5950</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331189/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331189/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30666128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Junfeng</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Ning, Jinzhuo</creatorcontrib><creatorcontrib>Yu, Weimin</creatorcontrib><creatorcontrib>Rao, Ting</creatorcontrib><creatorcontrib>Cheng, Fan</creatorcontrib><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer. Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities. These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</description><subject>Antisense RNA</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Colorectal cancer</subject><subject>Development and progression</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Immunohistochemistry</subject><subject>Liver cancer</subject><subject>Oncology, Experimental</subject><subject>Original Research</subject><subject>Polymerase chain reaction</subject><subject>Tumorigenesis</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkl2L1DAUhoso7rp65b0EBBGkYz7aJL0RhkFXYXBhnb0OaXPaZukkY5IK-3_8oWbccZ0RyUUOJ895k3PyFsVLgheUVOL91Waz-EYkayr8qDgnRMiSNww_PorPimcx3mLMuaTV0-KM5YgTKs-Ln2vvBuS867yxObr-ukQ3qyVBSYcBUkRbe13Wkpb1DmlnUOddCradE0SUPEojoF3wQ4AYrXe_ERPmAeWEjUm7DpDvUTtpYyCgbp_IG0xTLh-Dn4cRLTeXotyCsTqBQXpOfjfq4Q5ZN9rWpiz7vHjS6ynCi8N-Udx8-rhZfS7XV5dfVst12XFSp9JoLirS6pa3NTOYUNPUmveyxbyS0ErS4FYKTEnDW9EzIYTpQFMgDXAmTc8uig_3uru5zQ_qIPeqJ7ULdqvDnfLaqtMTZ0c1-B-KM0aIbLLA24NA8N9niEltbdx3qx34OSpKRMOauiYko6__QW_9HFxuT1FKMyNr3PylBj2Bsq73-d5uL6qWXApS4UqyTC3-Q-VlYGvzj0Fvc_6k4M1RwQh6SmP007wfdjwF392DXfAxBugfhkGw2rtPZfepg_sy_ep4fg_sH7uxX9FN1Js</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Wu, Junfeng</creator><creator>Li, Wei</creator><creator>Ning, Jinzhuo</creator><creator>Yu, Weimin</creator><creator>Rao, Ting</creator><creator>Cheng, Fan</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3691-5950</orcidid></search><sort><creationdate>20190101</creationdate><title>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</title><author>Wu, Junfeng ; Li, Wei ; Ning, Jinzhuo ; Yu, Weimin ; Rao, Ting ; Cheng, Fan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c615t-da6741bab6b53d012d95a6f8b0648eb8190b8702196b7f3777dcea2e19e638df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antisense RNA</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Colorectal cancer</topic><topic>Development and progression</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Immunohistochemistry</topic><topic>Liver cancer</topic><topic>Oncology, Experimental</topic><topic>Original Research</topic><topic>Polymerase chain reaction</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Junfeng</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Ning, Jinzhuo</creatorcontrib><creatorcontrib>Yu, Weimin</creatorcontrib><creatorcontrib>Rao, Ting</creatorcontrib><creatorcontrib>Cheng, Fan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Junfeng</au><au>Li, Wei</au><au>Ning, Jinzhuo</au><au>Yu, Weimin</au><au>Rao, Ting</au><au>Cheng, Fan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>12</volume><spage>495</spage><epage>508</epage><pages>495-508</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer. Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities. These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30666128</pmid><doi>10.2147/OTT.S183940</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-3691-5950</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2019-01, Vol.12, p.495-508
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6331189
source Taylor & Francis Open Access; DOVE Medical Press Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Antisense RNA
Apoptosis
Autophagy
Biomarkers
Bladder cancer
Cancer
Cancer therapies
Cell cycle
Cell growth
Colorectal cancer
Development and progression
Drug resistance
Drug therapy
Health aspects
Health risk assessment
Immunohistochemistry
Liver cancer
Oncology, Experimental
Original Research
Polymerase chain reaction
Tumorigenesis
title Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A26%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20noncoding%20RNA%20UCA1%20targets%20miR-582-5p%20and%20contributes%20to%20the%20progression%20and%20drug%20resistance%20of%20bladder%20cancer%20cells%20through%20ATG7-mediated%20autophagy%20inhibition&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Wu,%20Junfeng&rft.date=2019-01-01&rft.volume=12&rft.spage=495&rft.epage=508&rft.pages=495-508&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S183940&rft_dat=%3Cgale_pubme%3EA687140483%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2229558509&rft_id=info:pmid/30666128&rft_galeid=A687140483&rfr_iscdi=true